About Phenylethanolamine N-methyltransferase
Phenylethanolamine N-methyltransferase (PNMT) is a protein
from Homo sapiens identified by UniProt accession
P11086, 282 residues long.
MolForge cross-references it against 0 known binders and
126 disease associations.
Target properties
| Protein name | Phenylethanolamine N-methyltransferase |
| UniProt accession | P11086 |
| Gene | PNMT |
| Organism | Homo sapiens |
| Length | 282 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (126)
Diseases linked to this target (Open Targets).
- high density lipoprotein cholesterol measurement · score 0.27
- sleep duration · score 0.21
- cutaneous melanoma · score 0.19
- alcohol consumption measurement · score 0.13
- alkaline phosphatase measurement · score 0.13
- neurodegenerative disease · score 0.13
- self reported educational attainment · score 0.13
- age at menopause · score 0.11
- total cholesterol measurement · score 0.11
- physical activity · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11086-F1 | alphafold | PREDICTED | 93.92 | — |
Amino-acid sequence (282 residues)
MSGADRSPNA GAAPDSAPGQ AAVASAYQRF EPRAYLRNNY APPRGDLCNP NGVGPWKLRC LAQTFATGEV SGRTLIDIGS GPTVYQLLSA CSHFEDITMT DFLEVNRQEL GRWLQEEPGA FNWSMYSQHA CLIEGKGECW QDKERQLRAR VKRVLPIDVH QPQPLGAGSP APLPADALVS AFCLEAVSPD LASFQRALDH ITTLLRPGGH LLLIGALEES WYLAGEARLT VVPVSEEEVR EALVRSGYKV RDLRTYIMPA HLQTGVDDVK GVFFAWAQKV GL
Explore Phenylethanolamine N-methyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets